KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences

KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences
  • Home
  • About Us
    • Pipeline
    • Our Science
    • Our Publications
    • Our Patents
  • News
    • Presentations
    • Our Blog
  • Our Team
  • Contact
  • More
    • Home
    • About Us
      • Pipeline
      • Our Science
      • Our Publications
      • Our Patents
    • News
      • Presentations
      • Our Blog
    • Our Team
    • Contact
  • Home
  • About Us
    • Pipeline
    • Our Science
    • Our Publications
    • Our Patents
  • News
    • Presentations
    • Our Blog
  • Our Team
  • Contact

KAR101

KAR101 (Ramatroban), an orally bioavailable small molecule is a dual, reversible and potent antagonist of two G protein coupled receptors (i) Prostaglandin D2 (PGD2) receptor subtype DP2 (D prostanoid receptor 2; previously known as CRTH2) and (ii) thromboxane A2 (TxA2) receptors. Ramatroban (Baynas®, Bayer, Japan; dose: 50 mg and 75 mg tablets oral BID), also available as a generic from Kotobuki Pharma, Japan, has been safely and effectively used for the treatment of allergic rhinitis in Japan for the past 20 years. Given the scientific mechanisms and great potential that Ramatroban holds, KARE Biosciences aims to repurpose this drug for a variety of indications including COVID-19, sickle cell disease, Alzheimer's disease and silicosis. 

Our Science

COVID-19

Sickle Cell Disease

Sickle Cell Disease

Ramatroban (KAR101) is currently being tested in a randomized placebo-controlled trial of hospitalized COVID-19 patients in India (RAMBAN-1).

Discover More

Sickle Cell Disease

Sickle Cell Disease

Sickle Cell Disease

Discover More

Alzheimer's Disease

Alzheimer's Disease

Alzheimer's Disease

Discover More

Silicosis

Alzheimer's Disease

Alzheimer's Disease

Discover More

Ramatroban Package Insert (English)

Download PDF

Copyright © 2023 KARE Biosciences - All Rights Reserved.


Powered by GoDaddy